Collectively, ARID1A deficiency upregulates fatty acid metabolism to accelerate pancreatic tumourigenesis and FASN is a potential therapeutic target for ARID1A‐deficient pancreatic cancer. This evidence concerns the gene ARID1A and familial pancreatic carcinoma.